Gary John Schiller MD

Hematologic Oncology

Professor of Medicine, UCLA

10833 LeConte Ave42-121 CHSLos Angeles, CA 90095
Phone+1 310-825-5513
Fax+1 310-825-5513

Dr. Schiller is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schiller's full profile Already have an account?

Summary

Dr. Gary Schiller is an oncology specialist focused on hematologic oncology, practicing in Los Angeles, CA. He completed his fellowship in Hematology and Medical Oncology at UCLA, following an internal medicine residency at the same institution, graduating from the Keck School of Medicine. He has significant expertise in hematologic oncology, bone marrow transplantation, and leukemia, with notable research publications on acute myeloid leukemia. Dr. Schiller is actively involved in clinical trials as a principal investigator, particularly in gene transfer studies and treatments for hematologic malignancies. His contributions to the field have earned him several recognitions, including being named one of America's Top Doctors by Castle Connolly.

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1990
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1984 - 1987
Keck School of Medicine of the University of Southern CaliforniaClass of 1984

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1985 - 2027
FL State Medical License 2015 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
America's Top Doctors Castle Connolly, 2003-2014

Clinical Trials

Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer
COMPLETED
PHASE1, PHASE2
Gemtuzumab in Treating Patients With Myelodysplastic Syndrome
UNKNOWN
PHASE2
An Open-Label, Phase II (Proof Of Concept) Trial Of PKC412 Monotherapy In Patients With Acute Myeloid Leukemia (AML) And Patients With High Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2002 Mar 01

Publications & Presentations

PubMed

Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results.
Michael J Hochman, Amy S Ruppert, Ying Huang, Alice Mims, Uma Borate
Haematologica. 2026-11-01
5 citations
Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia.
Eunice S Wang, Harry Erba, Amer M Zeidan, Gail J Roboz, Jessica K Altman
Blood. 2026-10-01
A Phase 1b Study of Efmarodocokin Alfa, an Interleukin-22 Agonist, in Combination with Standard of Care, in Patients Undergoing Allogeneic Hematopoietic Stem Cell Tran...
Shukaib Arslan, Corey Cutler, Amin Alousi, Mehdi Hamadani, Sunil H Abhyankar
Transplantation and Cellular Therapy. 2026-10-01

Journal Articles

Phase 2b Study of Two Dosing Regimens of Quizartinib Monotherapy in FLT3-ITD Mutated, Relapsed or Refractory AML
Alexander E Perl, Stuart L Goldberg, Martin S Tallman, Hagop M Kantarjian, Gary J Schiller, Blood

Abstracts/Posters

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ...
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent _-Thalassemia in the Northstar (HGB-204) Study
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
Gary J. Schiller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

The Scientific Sessions from ASH 2021December 2021

Press Mentions

CIRM Grant Will Help Expand Patients’ Access to UCLA Clinical Trials for Stem Cell, Gene TherapiesOctober 27th, 2022
African-American Blood Donors Needed to Help People with Sickle Cell DiseaseOctober 4th, 2022
UCLA Jonsson Comprehensive Cancer Center Researchers at ASH 2021 Annual Meeting and ExpositionDecember 14th, 2021